Fusion Pharmaceuticals, Inc. (FUSN)

NASDAQ: FUSN · IEX Real-Time Price · USD
2.53
+0.04 (1.61%)
Jul 1, 2022 3:59 PM EDT - Market closed
1.61%
Market Cap 109.66M
Revenue (ttm) 2.03M
Net Income (ttm) -83.43M
Shares Out 43.34M
EPS (ttm) -1.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,390
Open 2.44
Previous Close 2.49
Day's Range 2.44 - 2.57
52-Week Range 2.41 - 9.50
Beta -0.59
Analysts Buy
Price Target 18.16 (+617.8%)
Earnings Date Aug 9, 2022

About FUSN

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-l... [Read more...]

Industry Biotechnology
IPO Date Jun 26, 2020
Employees 83
Stock Exchange NASDAQ
Ticker Symbol FUSN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for FUSN stock is "Buy." The 12-month stock price forecast is 18.16, which is an increase of 617.79% from the latest price.

Price Target
$18.16
(617.79% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational Small Molecule-Based Radiophar...

HAMILTON, ON and BOSTON , June 23, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...

Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434

- Study evaluates pre-administration of cold antibody prior to administration of imaging agent - Imaging shows favorable gain in tumor lesion uptake versus normal tissue when cold antibody is pre-admini...

Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement

Fusion to invest $5M for guaranteed access to actinium-225 supply Agreement augments Fusion's existing supply as company expands pipeline of actinium-based radio pharmaceuticals HAMILTON, ON and BOSTON ...

Fusion's stock falls 4% after announcing two clinical delays

Shares of Fusion Pharmaceuticals Inc. FUSN, -0.54% fell 4.3% in premarket trading on Thursday after the company announced several delays to its oncology program. Fusion said it wouldn't be able to share...

Fusion Pharmaceuticals Provides Updates on FPI-1434 and FPI-1966 Clinical Programs

HAMILTON, ON and BOSTON , June 9, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAMILTON, ON and BOSTON, June 8, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisio...

Fusion Pharmaceuticals to Present at the 2022 Jefferies Global Healthcare Conference

HAMILTON, ON and BOSTON, June 6, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisio...

Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day

HAMILTON, ON and BOSTON, May 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisio...

Fusion Pharmaceuticals Announces First Quarter 2022 Financial Results and Clinical Program Updates

Phase 1 data for FPI-1434 anticipated to be reported in the second half of 2022 Company continues to build a diversified pipeline of TATs and advance manufacturing and actinium supply chain capabilities...

Fusion Pharmaceuticals to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

HAMILTON, ON and BOSTON , April 26, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...

Oxford Finance Announces the Closing of a $75 Million Credit Facility With Fusion Pharmaceuticals

ALEXANDRIA, Va. & HAMILTON, Ontario--(BUSINESS WIRE)--Oxford Finance announces the closing of a $75 million credit facility with Fusion Pharmaceuticals

Fusion Pharmaceuticals Announces Fourth Quarter 2021 Financial Results and Clinical Program Updates

- Company is advancing first targeted alpha therapy (TAT) candidate under collaboration with AstraZeneca - Recently signed research collaborations support expansion of pipeline into peptide-based radiop...

Fusion Pharmaceuticals to Participate at the Cowen 42nd Annual Health Care Conference

HAMILTON, ON and BOSTON, Feb. 28, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...

Fusion Pharmaceuticals to Present at the B. Riley Securities 2022 Virtual Oncology Conference

HAMILTON, ON and BOSTON, Jan. 21, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...

Fusion Pharmaceuticals Announces Research Collaboration with Pepscan to Develop Peptide-Based Radiopharmaceuticals

HAMILTON, ON and BOSTON, Jan. 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...

Fusion Pharmaceuticals Announces Research Collaboration with 48Hour Discovery to Develop Peptide-Based Radiopharmaceu...

HAMILTON, Ontario and BOSTON, Jan. 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as pr...

Fusion Pharmaceuticals Announces Nomination of First Targeted Alpha Therapy Candidate in Collaboration with AstraZene...

Candidate Combines Fusion's Targeted Alpha Therapy (TAT) Technology with an AstraZeneca Bispecific Antibody HAMILTON, Ontario and BOSTON, Jan. 10, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasda...

Other symbols: AZN

Fusion Pharmaceuticals To Present At The 2021 Jefferies London Healthcare Conference

HAMILTON , Ontario and BOSTON, Nov. 11, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as p...

Fusion Pharmaceuticals Announces Third Quarter 2021 Financial Results and Clinical Program Update

FPI-1434 Phase 1 multi-dose data now expected in 2H 2022 FPI-1966 Phase 1 study initiated; first patient expected to be dosed in Q1 2022 FPI-2059 investigational new drug application (IND) on track for ...

Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer

-  Eric Burak, Ph.D. Appointed as Chief Technology Officer HAMILTON , Ontario and BOSTON, Nov. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focus...

Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting its FPI-1966 and FPI-2059 Targeted Alpha...

Single and multiple doses of FPI-1966 demonstrated therapeutic efficacy in a preclinical bladder xenograft model [ 225 Ac]-FPI-2059 demonstrated superior efficacy against [ 177 Lu]-IPN-1087 in a head-to...

Fusion Pharmaceuticals Appoints Mohit Rawat as President and Chief Business Officer

HAMILTON, ON and BOSTON, Sept. 28, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...

Fusion Pharmaceuticals To Present At The 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

HAMILTON, ON and BOSTON, Sept. 23, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...

Fusion Pharmaceuticals Appoints Eric S. Hoffman, Ph.D.

HAMILTON, ON and BOSTON, Sept. 21, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precis...

Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences

HAMILTON, ON and BOSTON, Sept. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precisi...